

# Differential virulence of camel *Trypanosoma evansi* isolates in mice

Christine M. Kamidi<sup>1,2,3</sup>, Joanna Auma<sup>2</sup>, Paul O. Mireji<sup>2,4</sup>, Kariuki Ndungu<sup>2</sup>, Rosemary Bateta<sup>2</sup>, Richard Kurgat<sup>2</sup>, Collins Ouma<sup>1</sup>, Serap Aksoy<sup>3</sup> and Grace Murilla<sup>2,3</sup>

## Research Article

**Cite this article:** Kamidi CM, Auma J, Mireji PO, Ndungu K, Bateta R, Kurgat R, Ouma C, Aksoy S, Murilla G (2018). Differential virulence of camel *Trypanosoma evansi* isolates in mice. *Parasitology* **145**, 1235–1242. <https://doi.org/10.1017/S0031182017002359>

Received: 10 July 2017

Revised: 4 December 2017

Accepted: 5 December 2017

First published online: 24 January 2018

### Key words:

Packed cell volume; survival; *Trypanosoma evansi*; virulence.

### Author for correspondence:

Christine M. Kamidi and Grace Murilla,  
E-mail: [tmuhonja@gmail.com](mailto:tmuhonja@gmail.com), [gmurilla@yahoo.co.uk](mailto:gmurilla@yahoo.co.uk)

<sup>1</sup>Department of Biomedical Sciences and Technology, School of Public Health and Community Development, Maseno University, Maseno, Kenya; <sup>2</sup>Biotechnology Research Institute (BioRI) – Kenya Agricultural and Livestock Research Organization (KALRO), P.O. Box 362, Kikuyu 00902, Kenya; <sup>3</sup>Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA and <sup>4</sup>Centre for Geographic Medicine Research Coast, Kenya Medical Research Institute, P.O. Box 428, Kilifi, Kenya

### Abstract

This study assessed the virulence of *Trypanosoma evansi*, the causative agent of camel trypanosomiasis (surra), affecting mainly camels among other hosts in Africa, Asia and South America, with high mortality and morbidity. Using Swiss white mice, we assessed virulence of 17 *T. evansi* isolates collected from surra endemic countries. We determined parasitaemia, live body weight, packed cell volume (PCV) and survivorship in mice, for a period of 60 days' post infection. Based on survivorship, the 17 isolates were classified into three virulence categories; low (31–60 days), moderate (11–30 days) and high (0–10 days). Differences in survivorship, PCV and bodyweights between categories were significant and correlated ( $P < 0.05$ ). Of the 10 Kenyan isolates, four were of low, five moderate and one (Type B) of high virulence. These findings suggest differential virulence between *T. evansi* isolates. In conclusion, these results show that the virulence of *T. evansi* may be region specific, the phenotype of the circulating parasite should be considered in the management of surra. There is also need to collect more isolates from other surra endemic regions to confirm this observation.

## Introduction

*Trypanosoma evansi*, an important camel pathogen, belongs to subgenus *Trypanozoon*, a group of trypanosomes with diverse mammalian hosts (Ngaira *et al.* 2003; Desquesnes *et al.* 2013). It was first isolated in Dera Ismail Khan district of Punjab India in 1880 from infected camels and equids (Tehseen *et al.* 2015). The parasite is also believed to have originated from Africa where, presently, it causes the trypanosomiasis (surra) in camels, horses, cattle, buffaloes, small ruminants and dogs (Ngaira *et al.* 2003).

Surra is therefore endemic in many tropical and subtropical countries wherever biting-fly vectors are present. These countries include North and eastern Africa, the Middle East, Indian sub-continent, central Asia, southern China and South America (Dávila *et al.* 1999; Njiru *et al.* 2004) and the Canary Islands (Luckins, 1988). Its major impact has been felt in the arid and semi-arid areas (Tekle and Abebe, 2001).

Cattle and water buffalo are important for draught power, meat, milk and also for capital investment for low-income farmers in the affected areas (Luckins, 1988). The current diagnostic tests are insufficient (Desquesnes *et al.* 2013) making it difficult to estimate both the direct and indirect economic losses attributable to *T. evansi* infections (Desquesnes *et al.* 2013). Most estimates are based on mortality and chemotherapeutic interventions. For example in the Philippines, the estimated losses due to mortality are approximately US\$ 1.1 million (Manuel, 1998) while in Indonesia the annual loss from morbidity and mortality is approximately US\$ 28 million (Payne *et al.* 1991).

*Trypanosoma evansi*, which is closely related to *Trypanosoma brucei brucei*, is adapted for mechanical transmission (Antoine-Moussiaux *et al.* 2009), whereas the latter is cyclically transmitted by tsetse flies (Hoare, 1972). A mechanical transmission is as a result of the loss of maxicircle kinetoplast DNA in *T. evansi* (Borst and Hoeijmakers, 1979), which lock the trypanosome in the bloodstream stages (Luckins, 1988). The absence of intermittent development in any insect vector has enabled *T. evansi* to spread beyond the tsetse fly belt of Africa to other areas in the world (Luckins, 1988; Desquesnes *et al.* 2013).

Trypanosomes produce biologically active substances which cause trypanosomiasis; these include: variable surface glycoproteins (VSG), enzymes, B-cell mitogen and T lymphocyte triggering factor (TLTF) (Bezie *et al.* 2014). Majority of *T. evansi* stocks express a VSG known as Rode Trypanozoon antigen (RoTat) type 1.2, a predominant VSG (Urakawa *et al.* 2001; Claes *et al.* 2002). In Kenya, types A and B *T. evansi*, characterized by presence and absence of RoTat 1.2 VSG gene, respectively, have been reported (Urakawa *et al.* 2001; Ngaira *et al.* 2005; Njiru *et al.* 2006). Type B has also been reported in Ethiopian dromedary camels (Birhanu *et al.* 2016). Overall, the prevalence of type B largely remains unknown (Njiru *et al.* 2010).

In order to compete for transmission to new hosts, some pathogens, including *T. evansi*, extract resources from the host, thereby causing damage (Mackinnon *et al.* 2008). This damage will depend on the level of virulence of the pathogen as the host immunity can aggravate selection of virulence. Pathogens, therefore, run the risk of killing their host and completely lose their ongoing source of transmission to new hosts. Virulence has been reported in many pathogens (Little *et al.* 2008; Mackinnon *et al.* 2008), measured by the survival rate of the host following infection. Little *et al.* (2008) proved that relative growth rates of two parasite isolates studied depended on the host genotype.

However, it is generally acknowledged that naïve animals succumb to an infection faster than the animals that have been previously exposed to the disease (Mackinnon *et al.* 2008). The trade-off hypothesis and its assumptions have been well-covered in malaria (Mackinnon *et al.* 2008). Depending on pathogen types, evolutionary outcomes may occur. Other studies have reported that cysteine proteases (CPs), which are members of the papain family, are expressed during the infective stages of the parasite's life cycle and are suspected to act as pathogenic factors in the mammalian host, where they also trigger prominent immune responses (Lalmanach *et al.* 2002). The aim of the present study, therefore, was to generate data that would enhance our understanding of virulence in *T. evansi* towards the development of novel approaches for management of the disease in camels.

## Materials and methods

### Ethical approval

All experimental protocols and procedures used in this study involving laboratory animals were reviewed and approved by

Institutional Animal Care and Use Committee (IACUC) of Kenya Agricultural and Livestock Research Institute –Biotechnology Research Institute (KALRO-BioRI) Ref: C/BioRI/4/325/II/1.

### Experimental animals

The study used 6–8 weeks old male Swiss White mice, each weighing 25–30 g live body weight. The animals were obtained from the Animal Breeding Unit at KALRO-BioRI, Muguga. The mice were housed in standard mouse cages and maintained on a diet consisting of commercial pellets (Unga® Kenya Ltd). All experiments were performed according to the guidelines set by the Institutional; Animal Care and Use Committee of KALRO-BioRI. Briefly, water was provided *ad libitum* (Kagira *et al.* 2007). All mice were acclimatized for 2-weeks, during which time they were screened and treated for the ecto and endoparasites using ivermectin (Ivermectin®, Anupco, Suffolk, England) (Ndung'u *et al.* 2008). During the 2-week quarantine period, pre-infection data were collected on body weights and packed cell volume twice a week prior to parasite inoculation.

### Trypanosoma evansi isolates and preparation of inoculum

A total of 17 isolates obtained from different geographic regions and mammalian host species were used in the study (Table 1). Seven of the 17 isolates were obtained from Swiss Tropical Institute, Basel (STIB) while the remaining 10 isolates were obtained from the KALRO-BioRI, Trypanosome bio-bank (Murilla *et al.* 2014). The parasite stabilates obtained from BioRI trypanosome bank were thawed, and their viability established through microscopy. The parasites were considered viable if motile parasites were observed through wet film under a microscope. The parasites were diluted in phosphate buffered

**Table 1.** Sample details of *T. evansi* phenotyped or this study showing sample ID, strain isolated with source and reference in footnote, kinetoplast DNA (kDNA) type, virulence levels based on survival of infected Swiss White mice following infection, locality of origin, host of isolation, and the year of isolation

Isolate ID <sup>source</sup>	Locality of origin	Host	Year of isolation	kDNA Type	Average survival time (range dpi; n = 6)	Virulence levels
KETRI 3576 <sup>a</sup>	Ngurunit, Kenya	Camel	1994	A	55.33 (44–60)	Low
KETRI 3573 <sup>a</sup>	Ngurunit, Kenya	Camel	1994	A	52.17 (18–60)	Low
KETRI 2737 <sup>a</sup>	Galana, Kenya	Camel	1985	A	43.83 (32–60)	Low
KETRI 3567 <sup>a</sup>	Athiriver, Kenya	Camel	1994	A	33.83 (10–60)	Low
KETRI 3575 <sup>a</sup>	Ngurunit, Kenya	Camel	1994	A	26.83 (16–40)	moderate
KETRI 3580 <sup>a</sup>	Loglogo, Kenya	Camel	1994	A	20.67 (12–27)	moderate
KETRI 2446 <sup>a</sup>	Marsabit, Kenya	Camel	1979	A	17.5 (11–24)	moderate
KETRI 3552 <sup>a</sup>	Isiolo, Kenya	Camel	1994	A	17.17 (9–29)	moderate
KETRI 3266 <sup>a</sup>	Samburu, Kenya	Camel	1990	A	15.67 (6–22)	moderate
KETRI 4035 <sup>b</sup>	Colombia	Horse	1973	A	10.83 (9–18)	High
KETRI 2479 <sup>a</sup>	Ngurunit, Kenya	Camel	1979	B	10.17 (8–15)	High
KETRI 4036 <sup>b</sup>	Kazakhstan	Bactrian camel	1995	A	6.33 (5–7)	High
KETRI 4039 <sup>b</sup>	China	Water buffalo	1983	A	5.83 (5–7)	High
KETRI 4034 <sup>b</sup>	Brazil	Dog	1986	A	5.83 (5–6)	High
KETRI 4038 <sup>b</sup>	Indonesia	Water buffalo	1982	A	5.00 (5)	High
KETRI 4040 <sup>b</sup>	Vietnam	Water buffalo	1998	A	5.00 (5)	High
KETRI 4037 <sup>b</sup>	Philippines	Water buffalo	1996	A	4.5 (4–5)	High

<sup>a</sup>Kenya Trypanosomiasis Research Institute.

<sup>b</sup>Swiss Tropical Institute Basel.

n, number of infected mice; dpi, days post infection.

Saline Glucose (PSG; pH 8.0), and their viability confirmed (Gichuki and Brun, 1999). Two immunosuppressed donor mice per isolate were each inoculated intraperitoneally (i.p) with 200  $\mu\text{L}$  of  $1 \times 10^5$  trypanosomes  $\text{mL}^{-1}$  (Gichuki and Brun, 1999). Immunosuppression was achieved by administration of cyclophosphamide at 300  $\text{mg kg}^{-1}$  per animal at 100  $\text{mg kg}^{-1}$  body-weight per day for 3 consecutive days (Murilla, *et al.* 2016). The animals were monitored for trypanosomes daily until parasites were detected in the peripheral blood. Thereafter, the parasitaemia was monitored three times a week up to the first peak ( $1 \times 10^9$  trypanosomes) parasitaemia (Herbert and Lumsden, 1976). At peak parasitaemia, the mice were euthanized by placing them in a chamber containing carbon dioxide ( $\text{CO}_2$ ) and bled from the heart into a tube containing EDTA (Gichuki and Brun, 1999).

The blood was pooled and parasitaemia density determined. The pooled blood was diluted in PSG buffer (pH 8.0). The number of trypanosomes was quantified using an improved Neubauer chamber and viewed under the microscope (Seamer *et al.* 1993). The first count ( $C_1$ ) and the second count ( $C_2$ ) were made through all the 16 squares of the haemocytometer and the average count  $C_{\text{av}}$  calculated.

#### Trypanosome inoculation into experimental mice

Six mice were used per isolate. Six additional animals were used as controls (not infected). The experimental mice were inoculated i.p with  $1 \times 10^5$  trypanosomes in 200  $\mu\text{L}$  of PSG (pH = 8.0). The mice in the control group were similarly injected with 200  $\mu\text{L}$  of PSG per mouse. All the infected animals were maintained as described above for 60 days post-infection (dpi).

#### Parameters monitored during the pathogenicity studies

To monitor anaemia, polycythaemia or dehydration for each group of experimental animals, the following parameters were recorded; the pre-patent period (pp) (day of the first appearance of the parasite in the blood), parasitaemia profiles and packed blood cell volume (PCV) as an indicator for the development of anaemia and survival.

#### Evaluation of parasitaemia in infected mice

A drop of blood from the mouse-tail was placed on a clean slide and covered using a cover slip and examined under a microscope (Seamer *et al.* 1993). The parasitaemia score was correlated to a score sheet, as outlined by Herbert and Lumsden (Herbert and Lumsden, 1976). Parasitaemia was determined daily for the first 14 days. The period taken from parasite inoculation to the first appearance of trypanosomes in blood was recorded for all groups. Thereafter, parasitaemia was determined and recorded twice weekly up to 60 dpi. Any observed mortalities were recorded on daily basis.

#### Survival

Each mouse was monitored daily for a period of 60 dpi. The end point of the infected mice was determined by observation of clinical signs such as lethargy and hackle hair, as well as PCV drop of approximately 25% with consistent high parasitaemia levels of  $1 \times 10^9/\text{mL}^{-1}$  for at least 3 consecutive days. The animals were sacrificed immediately by  $\text{CO}_2$  asphyxiation in accordance with guidelines of the Institutional Animal Care and Use Committee (IUCAC) as described by (Martinez-gutierrez *et al.* 2014) and recorded as dead animals. Mice surviving beyond this period (60 dpi), were sacrificed using carbon dioxide and the survival

time recorded as 60 days and categorized as censored data. Log rank  $P$  and the Wilcoxon  $P$  values were determined and used to test the null hypothesis that the survival curves are identical in all the *T. evansi* populations (O'Brien, 1998).

#### Assessment of PCV in infected and uninfected mice

Blood from infected mice and uninfected controls was collected from the tail vein using heparinized capillary tubes and sealed with plasticine at one end (Naessens *et al.* 2005). The sealed capillaries were centrifuged in a haematocrit centrifuge at 10 062g, for 5 min. PCV was read using the haematocrit reader and expressed as a percentage (%) of the total blood volume (Naessens *et al.* 2005). The PCV data were collected twice weekly for the experimental period of 60 dpi.

#### Assessment of body weights in infected and uninfected mice

Body weights of mice were determined using an analytical balance (Mettler Toledo PB 302<sup>®</sup>, Switzerland) and expressed in grams prior and after inoculation. Data on live body weights were recorded twice a week for a period of 2 weeks before inoculation and over the experimental period of 60 dpi. The differences in the weights were determined.

#### Data analysis

The analysis was done to test the significant differences between the isolates in PCV, parasitaemia and body weights. The data obtained from the study were summarized as means  $\pm$  standard error, while the differences between and within the means were analysed using one-way ANOVA. All analysis was conducted using GenStat (Nelder and Baker, 1972).  $P \leq 0.05$  were considered statistically significant.


## Results

#### Parasitaemia profiles and survival of infected mice

The pp for mice infected with the 17 different *T. evansi* isolate was in the range of 1–3 dpi with parasitaemia progressing to the peak within 3 days (Figs 1 and S1). Based on parasitaemia profiles and survival of the infected mice, three distinct virulent groups were identified: (1) low, exhibiting high intermittent parasitaemia, survival 31–60 dpi; (2): moderate, exhibiting high persistent parasitaemia, survival 11–30 days; and (3): high, exhibiting high persistent parasitaemia, survival period 0–10 days. Mice in the high virulent group died before any clinical signs were manifested (Table 1). Three of four isolates (KETRI 3573, 3576, 3567) classified as low virulence exhibited high intermittent parasitaemia, with more than one parasitaemia wave in some animals (Figs 1A, S1A and B). The highest parasitaemia score attained was  $1 \times 10^9$  trypanosomes  $\text{mL}^{-1}$ . Each mouse attained this score at least once in the first 10 dpi. Parasitaemia profiles were significantly different ( $P < 0.05$ ) between individual mice infected with the same isolate and between isolates (Table 2).

In contrast, high persistent parasitaemia with a peak score of  $1 \times 10^9$  was recorded in mice infected with isolates of moderate virulence (Figs 1C, D and S1C–E). There were no significant differences in parasitaemia profiles ( $P > 0.05$ ) between individual animals infected with any of the isolates in this group except KETRI 3552 whose profile was significantly different from the rest of the isolates (Table 2).

Mice infected with one isolate from Kenya (Type B) and 6 from Asia and South America exhibited very high persistent parasitaemia, but of a shorter duration when compared with the



**Fig. 1.** (A and B) Parasitaemia profiles of individual mice infected with low virulence *Trypanosoma evansi* isolates; KETRI 3573 and 2737. (C and D) Parasitaemia profiles of mice infected with moderate virulence *Trypanosoma evansi* isolates; KETRI 3580 and 2446. (E and F) Parasitaemia profiles of individual mice infected with high virulence *Trypanosoma evansi* isolates; 4038 and 2479. (M, mouse).

moderate virulence group. Significant differences ( $P < 0.05$ ) were observed between isolates of this group (Figs 1E, S1F–K and Table 2). These isolates were classified as highly virulent.

A comparison revealed significant differences ( $P < 0.05$ ) in parasitaemia scores between the 3 virulence groups. Four of five isolates classified as moderately virulent had a mean log parasitaemia score above 7.5; three of four low virulent isolates with a mean log score above 6.5 and six of nine high virulent isolates with a mean log score of approximately 6.5 and below. These results demonstrated that the mean parasitaemia scores of the high virulent isolates were low with high death rates recorded within a short period when compared with the moderate and low virulent parasites.

### Survival

Survival curves are shown in Fig. 2A–C, depicting the fraction of animals alive from the time of parasite inoculation (time 0; Fig. 2A). No deaths were recorded in the control group during the 60 days observation period. Of the low virulence group isolate,

KETRI 2737 depicted four successful event times (survival) when compared with two event times for animals infected with KETRI 3573 (high and intermittent parasitaemia). Log rank  $P$  and the Wilcoxon  $P$  values are provided in Table 3. Both the Log rank and the Wilcoxon  $P$  values obtained for the low virulence and high virulence showed significant differences ( $P < 0.01$ ) in survival at both early and later days of infection. Mice infected with parasites of moderate virulence showed significant similarities between individual animals within and between isolates (Table 3;  $P > 0.05$ ).

### Packed blood cell volume


The control (non-infected) mice generally maintained their pre-infection PCV values ( $29.9 \pm 0.99$ ) throughout the observation period of 60 days. However, a gradual decline in mice infected with different low virulence isolates was recorded (Figs 3A, B, S2A and B). Isolates of moderate virulence recorded rapid decline in PCV when compared with the control group (Figs 3C, D and S1C–E). Individual mice and different isolates recorded no significant difference.

**Table 2.** Comparison of mean packed cell volume change (%), mean parasitaemia and mean bodyweights change (%) values between various *Trypanosoma evansi* isolates following infection of mice at different virulence levels

Country of origin	Isolate ID	Virulence	Mean PCV change (%)	Mean Parasitaemia	Mean bodyweights change (%)
n/a	Controls	n/a	29.9 ± 0.99 <sup>a</sup>		9.0 ± 2.13 <sup>b</sup>
Brazil	KETRI 4036	High	2.0 ± 0.88 <sup>b</sup>	5.2 ± 0.21 <sup>i</sup>	-0.6 ± 0.46 <sup>fg</sup>
Indonesia	KETRI 4040	High	-3.3 ± 1.36 <sup>bc</sup>	6.1 ± 0.1 <sup>gh</sup>	6.3 ± 0.89 <sup>bcd</sup>
Kazakhstan	KETRI 4038	High	-4.0 ± 0.53 <sup>bc</sup>	6.2 ± 0.06 <sup>fgh</sup>	4.3 ± 0.71 <sup>bcdef</sup>
Vietnam	KETRI 4039	High	-4.6 ± 1.42 <sup>bc</sup>	6.6 ± 0.09 <sup>efg</sup>	4.5 ± 1.11 <sup>bcde</sup>
Swiss	KETRI 4037	High	-5.5 ± 1.11 <sup>bcd</sup>	6.0 ± 0.13 <sup>h</sup>	0.7 ± 1.34 <sup>efg</sup>
Colombia	KETRI 4034	High	-10.4 ± 6.64 <sup>cde</sup>	5.0 ± 0.04 <sup>i</sup>	0.4 ± 0.58 <sup>efg</sup>
Kenya	KETRI 3573	Low	-13.5 ± 3.92 <sup>def</sup>	6.1 ± 0.39 <sup>gh</sup>	17 ± 2.2 <sup>a</sup>
Kenya	KETRI 2479	High	-15.1 ± 2.12 <sup>ef</sup>	7.1 ± 0.16 <sup>cd</sup>	6.9 ± 0.93 <sup>bc</sup>
Kenya	KETRI 3576	Low	-16.4 ± 3.93 <sup>efg</sup>	6.8 ± 0.15 <sup>de</sup>	16.2 ± 2.04 <sup>a</sup>
Kenya	KETRI 3552	Moderate	-17 ± 3.95 <sup>efg</sup>	6.8 ± 0.24 <sup>de</sup>	-0.3 ± 1.28 <sup>efg</sup>
Philippines	KETRI 4035	High	-19.6 ± 3.38 <sup>fgh</sup>	7.1 ± 0.17 <sup>cd</sup>	-9.9 ± 2.11 <sup>h</sup>
Kenya	KETRI 3567	Low	-24.7 ± 4.29 <sup>gh</sup>	6.7 ± 0.37 <sup>def</sup>	7.8 ± 3.17 <sup>bc</sup>
Kenya	KETRI 2737	Low	-26.5 ± 1.31 <sup>hi</sup>	7.4 ± 0.03 <sup>bc</sup>	16.3 ± 3.22 <sup>a</sup>
Kenya	KETRI 3580	moderate	-28.3 ± 3.72 <sup>hi</sup>	7.8 ± 0.17 <sup>ab</sup>	3.0 ± 0.99 <sup>cdef</sup>
Kenya	KETRI 3266	High	-34 ± 2.13 <sup>ij</sup>	7.5 ± 0.1 <sup>bc</sup>	-2.7 ± 1.4 <sup>g</sup>
Kenya	KETRI 2446	moderate	-34.7 ± 3.54 <sup>ij</sup>	7.8 ± 0.15 <sup>ab</sup>	-0.7 ± 0.8 <sup>fg</sup>
Kenya	KETRI3575	moderate	-40.4 ± 2.57 <sup>j</sup>	8.0 ± 0.08 <sup>a</sup>	1.4 ± 2.82 <sup>defg</sup>
LSD			8.8	0.53	5.0
CV (%)			51.8	6.8	98.9

NB: Means followed by the same letter do not significantly differ ( $P=0.05$ ).

LSD: least significant difference; CV: coefficient of variation.



**Fig. 2.** Survival curves depicting the fraction of animals alive from the time (0) of parasite inoculation: (A) Survival curves of *Trypanosoma evansi* isolates of high virulence. (B) Survival curves of *Trypanosoma evansi* isolates of medium virulence. (C) Survival curves of *Trypanosoma evansi* isolates of low virulence.

**Table 3.** Rank tests for survival time of Swiss White mice infected with *Trypanosoma evansi* isolates of varied virulence obtained from different endemic regions of the world

Virulence categories	Rank test	Chi-square	DF	P value
Low	Logrank (mantel-Cox)	18.129	3	0.0004
	Breslow-Gehan-Wilcoxon	16.091	3	0.0011
Moderate	Logrank (mantel-Cox)	3.810	3	0.2827
	Breslow-Gehan-Wilcoxon	3.650	3	0.3018
High	Logrank (mantel-Cox)	70.470	8	<0.0001
	Breslow-Gehan-Wilcoxon	56.933	8	<0.0001

There were no PCV profiles available for the high virulence group due to short survival period that ranged from 4 to 10 days. The drop in PCV was of approximated 3%. There were significant differences in % PCV values between the controls and infected animals ( $P < 0.05$ ; Table 2). Generally, the results showed that very high and persistent parasitaemia levels were associated with a rapid drop in PCV values.

### Body weight profiles

A gradual increase in live body weights of  $9.0 \pm 2.13$  g was observed in all mice in the control group over the observation period of 60 days. A similar trend was observed in profiles of animals infected with isolates classified as low virulence ( $7.8 \pm 3.17$  to  $17 \pm 2.2$ ); (Figs 4A, B, S3A and B), three of which were significantly higher ( $P < 0.05$ ) than those of controls, with exception of KETRI 2737 where there was a decrease compared with the controls (Fig. 4B).


When compared with the control mice, rapid decline in body-weights was observed in mice infected with four of the moderate virulent isolates as shown in Figs 4D and S3C–E. However, no weight loss was observed in mice infected with the isolate

KETRI 3580 within the same category of classification (Fig. 4C). No body weight profiles are available for the high virulence group due to the short survival period.

### Discussion

The present study demonstrated the existence of different levels of virulence in *T. evansi* isolates from Kenya which ranged from low, moderate to high. Virulence was measured using parasitaemia, mortality (survivorship data), levels of anaemia and weight loss experienced by the host during the infection: these are positive indicators of the probability of host death as described by various authors (Mackinnon *et al.* 2008; Mekata *et al.* 2013). The high and persistent parasitaemia for periods of over 10 days was mainly associated with rapid decline in both packed cell volume and body weight, indicating disease severity. Our results also demonstrated that low and intermittent parasitaemia was associated with maintenance and in some cases, weight gain when compared with uninfected animals ( $P < 0.05$ ). The most pathogenic of the three categories was the moderate virulence category, which persisted in the host long enough, presenting the opportunity for horizontal transmission to new hosts to take place. The rapid death of the mice infected with the high virulent group of parasites suggested lack of a trade-off between the host and pathogen as would occur in epidemics; the animals did not survive long enough to allow multiplication and transmission to new hosts.

In the present study, the animals that were able to control parasitaemia (low virulence) were also able to control PCV and generally maintain live body weights. This concurs with observations made by Noyes *et al.* (2009) on main characteristics used to determine resistance to trypanosomiasis. Our findings also suggest that, where the majority of the infections (high virulence) lead to host death within 10 days, it is highly likely that transmission would cease immediately as in epidemics, concurring with observations of Mackinnon *et al.* (2008). Three *T. evansi* isolates showed intermittent parasitaemia in the low virulent group, suggesting possible development of new variants of the parasite in



**Fig. 3.** (A and B) per cent (%) Packed Cell Volume change profiles of individual mice infected with low virulence *Trypanosoma evansi* isolates; KETRI 3573 and 2737. (C and D) Percent (%) Changes in packed cell volume of individual mice infected with moderate virulence *Trypanosoma evansi* isolates; KETRI 3580 and 2446. (M, mouse).




Fig. 4. (A and B) bodyweight changes profiles of individual mice infected with low virulence *Trypanosoma evansi* isolates; KETRI 3573 and 2737. (C and D) bodyweight change profiles of individual mice infected with moderate virulence of *Trypanosoma evansi* isolates; KETRI 3580 and 2446. (M, mouse).

infected mice. Intermittent parasitaemia can be explained by the fact that parasites use different strategies to evade the mammalian hosts' immune system, one of which is population growth (Alizon *et al.* 2009). This helps the parasite to avoid elimination by specific potent immune responses (Vincendeau and Bouteille, 2006) and yield variants that proliferate and produce a new population. This is the basis of the antigenic variation that has posed challenges to vaccine development in trypanosomiasis (Magez *et al.* 2010). In a study using *Escherichia coli*, Berngruber *et al.* (2013) tested the theory 'that predicts that selection for pathogen virulence and horizontal transmission is highest at the onset of an epidemic but decreases thereafter, as the epidemic depletes the pool of susceptible hosts', providing proof that the virulent strain is strongly favoured in the early stage of the epidemic, but loses competition with the latent virus as prevalence increases. This could be the reason for high morbidity reported in camels in different parts of the world where the disease is endemic (Morrison *et al.* 1978).

Anaemia is an inevitable consequence of trypanosome infection (Murray and Dexter, 1988). According to Murray and Dexter (1988), the rapid drop of PCV is always correlated closely with the appearance of parasitaemia. Anaemia and weight loss are therefore two of several clinical signs of acute animal trypanosomiasis. In the present study, gradual decline in PCV was recorded in mice infected with isolates that exhibited intermittent parasitaemia; the drop-in body weights were also gradual with weight gain recorded in others. However, there was a rapid drop in the PCV in the animals that exhibited high and persistent parasitaemia with a rapid decline in bodyweights. This has been reported in studies on malaria where the virulent parasites that generated highest parasite densities exploited more of the host's resources, the red blood cells (Mackinnon *et al.* 2008). The trypanosome species infecting the animals and the geographical location also influence the clinical picture of the disease.

Our observations showed that intermittent parasitaemia was positively associated with low virulence, indicating that the mice were able to fight the infection, gain weight with a gradual decline

in PCV and survive for longer periods. This observation is consistent with previous reports (Eyob and Matios, 2013).

In the current study, an increase in body weight in mice infected with parasites of low virulence was observed despite the effect of infection in the majority of the animals during the early stages of infection. The increase could be related to the retention of body fluids in the form of oedema that accompanies trypanosomiasis (Steverding, 2008). It was shown that in rodent trypanosomiasis, there is a correlation between splenomegaly and parasitaemia; this has been demonstrated in *Trypanosoma lewisi* (Cherian and Dusanic, 1977).

In conclusion, the 17 *T. evansi* isolates investigated were able to infect mice, multiply and cause disease. The different levels of virulence exhibited may be related to the host from which the parasites were isolated as well as the geographical location from where the isolates were collected. However, the factors underlying this difference in virulence levels are yet to be elucidated using molecular techniques. Animals infected with non-RoTat *T. evansi* Types A (Ngaira *et al.* 2005) and B (Njiru *et al.* 2006) may remain a source of infection for a long time, resulting in high mortality and morbidity further complicating the search for new diagnostics and vaccines to effectively control the disease in domestic animals.

**Supplementary material.** The supplementary material for this article can be found at <https://doi.org/10.1017/S0031182017002359>.

**Acknowledgements.** We thank the staff of Chemotherapy division especially B. Wanyonyi and J. Makau (posthumously) for their assistance with sample *Trypanosoma* processing, preparation and all animal experiments. We are grateful to Prof Reto Brun for providing *T. evansi* stabilates from STIB. Special thanks to the Director General KALRO for allowing us to access and use the parasites stored in the cryobank and publish this work. All authors have read and approved the final version of the manuscript.

**Financial support.** This work received financial support from Fogarty Global Infectious Diseases Training Grant D43TW007391, NIH R01 award AI068932 and 5T32AI007404-24 and from IAEA Contract No. 16181/RO awarded to Dr Rosemary Bateta.

## References

- Alizon S, Hurford A, Mideo N and Van Baalen M (2009) Virulence evolution and the trade-off hypothesis: history, current state of affairs and the future. *Journal of Evolutionary Biology* **22**(2), 245–259.
- Antoine-Moussiaux N, Büscher P and Desmecht D (2009) Host-parasite interactions in trypanosomiasis: on the way to an antidisease strategy. *Infection and Immunity* **77**(4), 1276–1284.
- Berngruber TW, Froissart R, Choisy M and Gandon S (2013) Evolution of virulence in emerging epidemics. *PLoS Pathogens* **9**(3), e1003209.
- Bezie M, Girma M, Dagnachew S, Tadesse D and Tadesse G (2014) African trypanosomes: virulence factors, pathogenicity and host responses. *Journal of Veterinary Advances* **4**(11), 732–745.
- Birhanu H, Gebrehiwot T, Goddeeris BM, Büscher P and Van Reet N (2016) New *Trypanosoma evansi* Type B isolates from Ethiopian dromedary camels. *PLoS Neglected Tropical Diseases* **10**(4), e0004556.
- Borst P and Hoëijmakers JH (1979) Kinetoplast DNA. *Plasmid* **2**(1), 20–40.
- Cherian PV and Dusanic D (1977) *Trypanosoma lewisi*: immunoelectron microscopic studies on the surface antigens of bloodstream forms. *Experimental Parasitology* **43**(1), 128–142.
- Claes F, Verloo D, De Waal DT, Urakawa T, Majiwa P, Goddeeris BM and Büscher P (2002) Expression of RoTat 1.2 cross-reactive variable antigen type in *Trypanosoma evansi* and *Trypanosoma equiperdum*. *Annals of the New York Academy of Sciences* **969**, 174–179.
- Dávila AMR, Souza SS, Campos C and Silva RAMS (1999) The seroprevalence of equine trypanosomosis in the pantanal. *Memorias Do Instituto Oswaldo Cruz* **94**(2), 199–202.
- Desquesnes M, Dargantes A, Lai DH, Lun ZR, Holzmüller P and Jittapalpong S (2013) *Trypanosoma evansi* and surra: a review and perspectives on transmission, epidemiology and control, impact, and zoonotic aspects. *BioMed Research International* **2013**, 321237.
- Eyob E and Matios L (2013) Review on camel trypanosomosis (surra) due to *Trypanosoma evansi*: epidemiology and host response. *Journal of Veterinary Medicine and Animal Health* **5**(12), 334–343.
- Gichuki C and Brun R (1999) Animal models of CNS (second-stage) sleeping sickness. In Zak O and Sande M (eds). *Handbook of Animal Models of Infection*. London, United Kingdom: Academic Press, pp. 795–800.
- Herbert WJ and Lumsden WHR (1976) *Trypanosoma brucei*: a rapid 'matching' method for estimating the host's parasitemia. *Experimental Parasitology* **40**(3), 427–431.
- Hoare CA (1972) *The Trypanosomes of Mammals: A Zoological Monograph*. Oxford, UK: Blackwell Scientific Publications.
- Kagira JM, Ngotho M and Thuita J (2007) Development of a rodent model for late stage rhodesian sleeping sickness. *Journal of Protozoology Research* **17**, 48–56.
- Lalmanach G, Boulangé A, Serveau C, Lecaillon F, Scharfstein J, Gauthier F and Authié E (2002) Congopain from *Trypanosoma congolense*: drug target and vaccine candidate. *Biological Chemistry* **383**, 739–749.
- Little TJ, Chadwick W and Watt K (2008) Parasite variation and the evolution of virulence in a Daphnia-microparasite system. *Parasitology* **135**(3), 303–308.
- Luckins AG (1988) *Trypanosoma evansi* in Asia. *Parasitology Today* **4**(5), 137–142.
- Mackinnon MJ, Gandon S and Read AF (2008) Virulence evolution in response to vaccination: the case of malaria. *Vaccine* **26**, C42–C52.
- Magaz S, Caljon G, Tran T, Stijlemans B and Radwanska M (2010) Current status of vaccination against African trypanosomiasis. *Parasitology* **137**(14), 2017–2027.
- Manuel MF (1998) Sporadic outbreaks of surra in the Philippines and its economic impact. *Journal of Protozoology Research* **8**, 131–138.
- Martinez-gutierrez M, A Correa-london L, Castellanos JE, Gallego-Gomez JC and Osorio JE (2014) Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. *PLoS ONE* **9**(2), e87412.
- Mekata H, Konnai S, Mingala CN, Abes NS, Gutierrez CA, Dargantes AP, Witola WH, Inoue N, Onuma M, Murata S and Ohashi K (2013) Isolation, cloning, and pathologic analysis of *Trypanosoma evansi* field isolates. *Parasitology Research* **112**(4), 1513–1521.
- Morrison WI, Roelants GE, Mayor-Withey KS and Murray M (1978) Susceptibility of inbred strains of mice to *trypanosoma congolense*: correlation with changes in spleen lymphocyte populations. *Clinical and Experimental Immunology* **32**(1), 25–40.
- Murilla G, Ndong'u K, Joanna A, Purity G and Thuita J (2016) Isolation and cryopreservation of *Trypanosomes* and their vectors for research and development in resource-constrained settings. In Francisco Marco-Jiménez and Hülya Akdemir (eds). *Cryopreservation in Eukaryotes*. InTech. doi: 10.5772/65283.
- Murilla GA, Ndong'u K, Thuita JK, Gitonga PK, Kahiga DT, Auma JE, Ouma JO, Rutto JJ and Ndong'u JM (2014) Kenya Trypanosomiasis Research Institute cryobank for human and animal trypanosome isolates to support research: opportunities and challenges. *PLoS Neglected Tropical Diseases* **8**(5), e2747.
- Murray M and Dexter TM (1988) Anaemia in bovine African trypanosomiasis. A review. *Acta Tropica* **45**(4), 389–432.
- Naessens J, Kitani H and Nakamura Y (2005) TNF- $\alpha$  mediates the development of anaemia in a murine *Trypanosoma brucei rhodesiense* infection, but not the anaemia associated with a murine *Trypanosoma congolense* infection. *Clinical and Experimental Immunology* **139**(3), 405–410.
- Ndong'u K, Ngotho M, Kinyua J, Kagira J, Guya S, Ndong'u J and Murilla G (2008) Pathogenicity of bloodstream and cerebrospinal fluid forms of *Trypanosoma brucei rhodesiense* in Swiss White Mice. *African Journal of Health Sciences* **15**(1), 34–41.
- Nelder JA and Baker RJ (1972) *Generalized linear models*. John Wiley & Sons, Inc.
- Ngaira JM, Bett B, Karanja SM and Njagi ENM (2003) Evaluation of antigen and antibody rapid detection tests for *Trypanosoma evansi* infection in camels in Kenya. *Veterinary Parasitology* **114**, 131–141.
- Ngaira JM, Olembi NK, Njagi ENM and Ngeranwa JN (2005) The detection of non-RoTat 1.2 *Trypanosoma evansi*. *Experimental Parasitology* **110**(1), 30–38.
- Njiru ZK, Constantine CC, Masiga DK, Reid SA, Thompson RCA and Gibson WC (2006) Characterization of *Trypanosoma evansi* type B. *Infection, Genetics and Evolution* **6**(4), 292–300.
- Njiru ZK, Constantine CC, Ndong'u JM, Robertson I, Okaye S, Thompson RCA and Reid SA (2004) Detection of *Trypanosoma evansi* in camels using PCR and CATT/T. *evansi* tests in Kenya. *Veterinary Parasitology* **124**(3), 187–199.
- Njiru ZK, Ouma JO, Enyaru JC and Dargantes AP (2010) Loop-mediated isothermal amplification (LAMP) test for detection of *Trypanosoma evansi* strain B. *Experimental Parasitology* **125**(3), 196–201.
- Noyes HA, Alimohammadian MH, Agaba M, Brass A, Fuchs H, Gailus-Durner V, Hulme H, Iraqi F, Kemp S, Rathkolb B and Wolf E (2009) Mechanisms controlling anaemia in *Trypanosoma congolense* infected mice. *PLoS ONE* **4**(4), e5170.
- O'Brien PC (1998) Comparing two samples: extensions of the t, rank-sum, and log-rank tests. *Journal of the American Statistical Association* **83**(401), 52–61.
- Payne RC, Djauhari D, Partoutomo S, Jones TW and Pearson RA (1991) *Trypanosoma evansi* infection in worked and unworked buffaloes (*Bubalus bubalis*) in Indonesia. *Veterinary Parasitology* **40**(3–4), 197–206.
- Seamer J, Southee J, Thompson A, Trussell B, West C and Jennings M (1993) Removal of blood from laboratory mammals and birds. *Laboratory Animals* **27**(1), 1–22.
- Stevard D (2008) The history of African trypanosomiasis. *Parasites and Vectors* **1**(1), 3.
- Tehseen S, Jahan N, Qamar MF, Desquesnes M, Shahzad MI, Deborggraeve S and Büscher P (2015) Parasitological, serological and molecular survey of *Trypanosoma evansi* infection in dromedary camels from Cholistan Desert, Pakistan. *Parasites and Vectors* **8**(1), 415.
- Tekle T and Abebe G (2001) Trypanosomosis and helminthoses: major health problems of camels (*Camelus dromedaries*) in the southern rangelands of Borena, Ethiopia. *Journal of Camel Practice and Research* **8**(1), 39–42.
- Urakawa T, Verloo D, Moens L, Büscher P and Majiwa PA (2001) *Trypanosoma evansi*: cloning and expression in *Spodoptera frugiperda* [correction of *fugiperda*] insect cells of the diagnostic antigen RoTat1.2. *Experimental Parasitology* **99**, 181–189.
- Vincendeau P and Bouteille B (2006) Immunology and immunopathology of African trypanosomiasis. *Anais Da Academia Brasileira de Ciencias* **78**(4), 645–665.